Emergent Biosolutions Inc (N:EBS)

May 01, 2024 04:57 pm ET
Emergent BioSolutions Reports First Quarter 2024 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent....
May 01, 2024 04:10 pm ET
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and...
May 01, 2024 11:03 am ET
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students,...
Apr 30, 2024 05:26 pm ET
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility. “In light of this amendment, Emergent now has an extended runway to execute on our go-forward...
Apr 22, 2024 08:05 am ET
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of...
Apr 01, 2024 08:00 am ET
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the...
Mar 28, 2024 08:15 am ET
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S. Centers for Disease...
Mar 25, 2024 08:05 am ET
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the...
Mar 06, 2024 04:31 pm ET
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long history of helping protect people around the world from opioid overdose emergencies and chemical,...
Feb 29, 2024 07:00 am ET
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph...
Feb 21, 2024 07:00 am ET
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president...
Jan 11, 2024 08:00 am ET
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by...
Jan 09, 2024 07:30 am ET
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich...
Nov 28, 2023 06:59 am ET
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human...
Nov 24, 2023 07:30 am ET
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing...
Nov 08, 2023 05:38 pm ET
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financial results reported include limited third quarter and year-to-date results, as well as selected...
Oct 30, 2023 04:45 pm ET
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for...
Oct 19, 2023 06:30 am ET
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full...
Oct 16, 2023 07:00 am ET
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
Professional Football Hall of Famer partners with Emergent to raise awareness of the dangers of opioid use and the importance of being prepared with NARCAN® Nasal SprayThe life-saving medicine is available over the counter nationwide, making it possible for anyone to save a lifeGAITHERSBURG, Md., Oct. 16, 2023 /PRNewswire/ -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is teaming up with football icon, Emmitt Smith, to break down the stigma around opioid use and accidental overdose, which continues to fuel a national epidemic impacting people from all walks of life.1  During h
Oct 02, 2023 07:00 am ET
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined...
Sep 20, 2023 03:09 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Emergent BioSolutions Inc., James River Group Holdings, Ltd., Edgio, Inc., and Hanmi Financial Corporation. If you are a current owner of...
Aug 30, 2023 05:59 am ET
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
Today, Emergent BioSolutions Inc. (NYSE: EBS) announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September. Over-the-counter (OTC) access to NARCAN® Nasal Spray offers more people the...
Aug 08, 2023 04:31 pm ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business. “Emergent has...
Aug 08, 2023 07:15 am ET
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result, Emergent is reducing operations at its Bayview facility in Baltimore, Maryland....
Jul 31, 2023 04:05 pm ET
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within...
Jul 25, 2023 06:30 am ET
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third...
Jul 20, 2023 06:03 pm ET
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following...
Jun 27, 2023 07:55 am ET
Emergent BioSolutions Announces CEO Transition
Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent. Mr. Kramer will step down from his role as President and CEO of...
May 15, 2023 07:58 am ET
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At closing Emergent received $270 million, subject to customary closing adjustments, and may receive up to an...
May 11, 2023 06:30 am ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL...
May 09, 2023 04:05 pm ET
Emergent BioSolutions Reports Financial Results For First Quarter 2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2023. Among the highlights, Emergent has received from the U.S. government Notices of Intent to Purchase medical countermeasures to combat...
Apr 19, 2023 04:05 pm ET
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second...
Apr 10, 2023 09:31 am ET
Thinking about buying stock in Eloxx Pharmaceuticals, Micron Technology, Emergent Biosolutions, Inflarx NV, or TG Therapeutics?
NEW YORK, April 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELOX, MU, EBS, IFRX, and TGTX.
Mar 29, 2023 09:48 am ET
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at...
Mar 09, 2023 07:30 am ET
Thinking about buying stock in Unicycive Therapeutics, Asana, Emergent Biosolutions, Cassava Sciences, or FuelCell Energy?
NEW YORK, March 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNCY, ASAN, EBS, SAVA, and FCEL.
Feb 27, 2023 04:42 pm ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2022. “Our 2022 performance reflects the transition the company is undergoing and, together with our 2023 forecast, stands...
Feb 16, 2023 07:36 am ET
Thinking about buying stock in Virgin Galactic, Emergent Biosolutions, Hexo, Community Health Systems, or DigitalOcean?
NEW YORK, Feb. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, EBS, HEXO, CYH, and DOCN.
Feb 15, 2023 05:19 pm ET
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have unanimously voted in favor (a total...
Feb 15, 2023 02:00 am ET
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the...
Feb 06, 2023 04:05 pm ET
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, February 27, 2023, at 5:00 pm eastern time to discuss the financial results for the fourth quarter of 2022, recent business developments, and financial outlook for full...
Jan 09, 2023 06:59 am ET
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through its core businesses, consisting of medical countermeasures (MCM) and commercial products, including NARCAN® (naloxone HCl) Nasal...
Jan 06, 2023 07:48 am ET
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions?
NEW YORK, Jan. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRB, CTMX, BOXD, MGAM, and EBS.
Jan 05, 2023 05:30 pm ET
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use...
Dec 06, 2022 06:00 am ET
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for NARCAN® (naloxone HCI) Nasal Spray, as an over-the-counter (OTC)...
Nov 14, 2022 06:30 am ET
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like...
Nov 08, 2022 04:16 pm ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022. “For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allied governments, in...
Nov 01, 2022 04:05 pm ET
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in prior recipients of...
Oct 27, 2022 08:30 am ET
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,...
Oct 18, 2022 06:30 am ET
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full...
Sep 26, 2022 04:12 pm ET
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age...
Sep 06, 2022 06:30 am ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for...
Aug 10, 2022 06:30 am ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor ConferenceChicago, ILAugust 24, 2022 –...
Aug 01, 2022 04:05 pm ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022. “Central to Emergent's mission - to protect and enhance life - is our ability to provide quality products and services for the...
Jul 18, 2022 04:05 pm ET
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third...
Jul 07, 2022 04:30 pm ET
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to...
Jul 06, 2022 04:05 pm ET
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023 annual meeting of...
Jul 06, 2022 06:00 am ET
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed...
Jun 24, 2022 06:30 am ET
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s new...
Jun 21, 2022 06:30 am ET
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine...
Jun 02, 2022 08:20 am ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 ConferenceJune 2, 2022 NYSE...
May 25, 2022 05:57 pm ET
May 23, 2022 08:30 am ET
Thinking about buying stock in SIGA Technologies, Geovax Labs, Inovio Pharmaceuticals, ImmunoGen, or Emergent Biosolutions?
NEW YORK, May 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SIGA, GOVX, INO, IMGN, and EBS.
May 20, 2022 08:31 am ET
Thinking about buying stock in Rivian Automotive, Siyata Mobile, Emergent Biosolutions, Stryve Foods, or IQIYI?
NEW YORK, May 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIVN, SYTA, EBS, SNAX, and IQ.
May 18, 2022 01:39 pm ET
May 16, 2022 06:32 am ET
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimerix, Inc. (NASDAQ: CMRX), to acquire Chimerix’s exclusive worldwide rights to TEMBEXA® (brincidofovir), the first antiviral approved...
May 12, 2022 06:30 am ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL...
May 10, 2022 04:42 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.
NEW YORK, May 10, 2022 /PRNewswire/ -- Weiss Law, a national shareholders' rights law firm, is investigating possible false claims, deceptive accounting and reporting practices, breaches of fiduciary duty, and violations of the federal securities laws by the Board of Directors and certain Company officers of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). According to a final report expected to be released today after a year-long investigation by the House of Representatives' Select Subcommittee on the Coronavirus Crisis, the Company, hired to produce hundreds of millio
Apr 28, 2022 04:05 pm ET
Emergent BioSolutions Reports Financial Results For First Quarter 2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022. “Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients...
Apr 08, 2022 06:30 am ET
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second...
Mar 23, 2022 04:05 pm ET
Emergent BioSolutions Provides Corporate Governance Update
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its board of directors (the “board”) has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance. Effective...
Mar 14, 2022 04:05 pm ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: KeyBanc Life Sciences & MedTech Investor ForumMarch 22, 2022Company fireside...
Mar 11, 2022 06:34 am ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being...
Feb 24, 2022 04:05 pm ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2021. "Emergent’s performance in 2021 is a testament to our strategic focus and highly capable team," said Robert G. Kramer,...
Feb 07, 2022 06:30 am ET
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year...
Jan 14, 2022 06:30 am ET
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022. “Creating and leading Emergent has been the honor of my life, and it would not have been...
Jan 09, 2022 02:00 pm ET
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021. “This past year we celebrated wins across the business and overcame our share of challenges, which...
Jan 03, 2022 06:30 am ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022: 40th Annual J.P. Morgan Healthcare Conference...
Dec 16, 2021 07:30 am ET
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate....
Nov 23, 2021 08:45 am ET
Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Grey, Aadi Bioscience, or Emergent Biosolutions?
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, NVTS, BGRY, AADI, and EBS.
Nov 22, 2021 05:00 pm ET
SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600
NEW YORK, Nov. 22, 2021 /PRNewswire/ -- SiTime Corp. (NASD: SITM) will replace Emergent BioSolutions Inc. (NYSE: EBS) in the S&P MidCap 400, and Emergent BioSolutions will replace Domtar Corp. (NYSE: UFS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 30. Paper Excellence B.V. is acquiring Domtar in a deal expected to be completed soon pending final conditions. Emergent BioSolutions is more representative of the small-cap market space.
Nov 11, 2021 04:05 pm ET
Emergent BioSolutions Announces Stock Repurchase Program
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized management to repurchase up to $250 million of the company's common stock from time to time on the open market or in privately negotiated...
Nov 04, 2021 04:05 pm ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2021. "Emergent's core products and service businesses remain strong as evidenced by our accomplishments this quarter," said Robert...
Nov 02, 2021 09:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Live Ventures, CorMedix, Emergent BioSolutions, and Generac on Behalf of Long-Term Stockholders and Encourages Investors to Con
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Live Ventures Incorporated (NASDAQ: LIVE), CorMedix Inc. (NASDAQ: CRMD), Emergent BioSolutions, Inc. (NYSE: EBS),...
Nov 02, 2021 09:00 am ET
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the...
Oct 18, 2021 06:30 am ET
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full...
Oct 15, 2021 06:30 am ET
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine...
Oct 12, 2021 09:24 am ET
Did You Acquire (EBS) Before April 24, 2020? Johnson Fistel Investigates Emergent; Should Management be Held Accountable for Investors Losses?
Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors.  If you are a current shareholder of Emergent, holding...
Sep 21, 2021 01:23 pm ET
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE:
Sep 14, 2021 08:00 am ET
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development...
Aug 25, 2021 06:30 am ET
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient T
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient...
Aug 23, 2021 04:05 pm ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Three Part Advisors IDEAS Midwest Conference August 25-26, 2021 Pre-recorded...
Aug 21, 2021 02:40 pm ET
EBS Long Term Investor Alert: Did You Acquire (EBS) Before April 24, 2020? – Johnson Fistel Continues its Investigation
Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors. Recently a class action lawsuit was filed in federal court...
Aug 19, 2021 08:57 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Emergent BioSolutions, Peloton, and Vroom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Emergent BioSolutions, Inc. (NYSE: EBS), Peloton Interactive, Inc. (NASDAQ: PTON), and Vroom, Inc. (NASDAQ: VRM) on...
Jul 30, 2021 06:51 pm ET
EBS Long Term Investor Alert: Did You Acquire (EBS) Before April 24, 2020? - Contact Johnson Fistel Regarding Investigation
Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors. Recently a class action lawsuit was filed in federal court...
Jul 29, 2021 04:05 pm ET
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. “Our second quarter performance demonstrates the strength of our strategy and diversified business model,” said Robert G. Kramer,...
Jul 29, 2021 07:24 am ET
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance....
Jul 26, 2021 09:01 am ET
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
An alliance of national nonprofit organizations comprised of Community Anti-Drug Coalitions of America (CADCA), Mothers Against Prescription Drug Abuse (MAPDA), SAFE Project, and Shatterproof, sponsored by Emergent BioSolutions Inc., (NYSE:EBS)...
Jul 20, 2021 07:25 am ET
EBS Long Term Investor Alert: Did You Acquire (EBS) Before April 24, 2020? - Contact Johnson Fistel Regarding Investigation
Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors. Recently, a class action lawsuit was filed in federal court...
Jul 15, 2021 06:30 am ET
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third...
Jun 24, 2021 09:19 am ET
Did You Acquire (EBS) Before April 24, 2020? Johnson Fistel Investigates Emergent; Should Management be Held Accountable for Investors Losses?
Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors.  Recently a class action lawsuit was filed in federal court...
Jun 20, 2021 10:42 am ET
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. (“Emergent BioSolutions” or “the Company”) (NYSE:
Jun 19, 2021 08:27 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. (“Emergent BioSolutions” or “the Company”) (NYSE:
Jun 18, 2021 10:11 am ET
EBS UPDATED DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Informs Emergent BioSolutions Inc. Investors of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court H
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the “Class Period”), of the important June 21, 2021...
Jun 17, 2021 07:00 pm ET
EMERGENT BIOSOLUTIONS 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Again
NEW ORLEANS, June 17, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 18, 2021 to file lead plaintiff applications in securities class action lawsuits against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between April 24, 2020 and April 16, 2021, inclusive (the "Class Period").  These actions are pending in the United States District Court for the District of Maryland.
Jun 17, 2021 11:00 am ET
Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 17, 2021 10:05 am ET
Kessler Topaz Meltzer & Checker, LLP:  Final Deadline Reminder for Emergent BioSolutions Inc. Investors – EBS
The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the “Class Period”). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the “Roth Action”), was filed in the United States District Court for the District of Maryland (Southern Division). To view a copy
Jun 17, 2021 09:06 am ET
EBS INVESTOR DEADLINE TOMORROW: Hagens Berman Encourages Emergent BioSolutions (EBS) Investors with Losses to Contact the Firm Now, Securities Fraud Lawsuit Pending
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs...
Jun 16, 2021 10:26 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EBS, PTON, RLX, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Emergent BioSolutions Inc. (EBS)Class Period:...
Jun 16, 2021 10:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of investors that purchased Emergent BioSolutions, Inc. (NYSE: EBS) common stock between April 24, 2020 and April 16, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 16, 2021 05:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 15, 2021 11:06 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of EBS, PTON, RLX and UI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Emergent BioSolutions Inc. (EBS)Class Period: April 24, 2020 and April 16, 2021Lead Plaintiff Motion Deadline:...
Jun 15, 2021 04:51 pm ET
3 Day Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Against Emergent BioSolutions Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired...
Jun 15, 2021 12:44 pm ET
Emergent BioSolutions, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Emergent BioSolutions, Inc. (NYSE: EBS) investors that acquired shares between April 24, 2020, and April 16, 2021. Investors have until June 18, 2021 to...
Jun 14, 2021 10:56 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, PTON, RLX, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Emergent BioSolutions Inc. (EBS)Class Period: 4/24/2020 - 4/16/2021Lead Plaintiff Motion Deadline: June...
Jun 14, 2021 08:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jun 14, 2021 11:05 am ET
EBS Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 18, 2021 Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa., June 14, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period").  This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the "Roth Action"), was filed in the United States District Court for the District of Maryland (Southern Division).  To view a copy of
Jun 14, 2021 10:00 am ET
FUV, ACAD & EBS Few Days Left to Actively Participate in Class Actions: Bronstein, Gewirtz & Grossman LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 12, 2021 12:06 pm ET
EBS 6-DAY DEADLINE ALERT: Hagens Berman Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Before June 18th Deadline in Securities Fraud Action
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 11, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EBS, PTON, RLX, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Emergent BioSolutions Inc. (EBS)Class Period:...
Jun 11, 2021 04:35 pm ET
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA)...
Jun 11, 2021 12:10 pm ET
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired Emergent common stock...
Jun 11, 2021 12:03 pm ET
EBS FINAL DEADLINE NOTICE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 18 Dead
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the “Class Period”), of the important June 18, 2021...
Jun 09, 2021 09:33 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, PTON, RMO, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Romeo Power, Inc. (RMO) f/k/a RMG Acquisition Corp. (RMG)Class Period: 10/5/2020 - 3/30/2021Lead...
Jun 09, 2021 10:00 am ET
FUV, ACAD & EBS Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines: June 18, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 08, 2021 10:48 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, EBS and RMO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canaan Inc. (CAN)Class Period: February 10, 2021 and April 9, 2021Lead Plaintiff Motion Deadline: June 14,...
Jun 08, 2021 05:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jun 08, 2021 02:52 pm ET
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
RADNOR, Pa., June 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the "Roth Action"), was filed in the United States District Court for the District of Maryland (Southern Division). To view a copy of the
Jun 07, 2021 11:13 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
Jun 07, 2021 07:19 pm ET
EBS Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Against Emergent BioSolutions Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that the firm has filed a securities fraud class action lawsuit in the United States District Court for the District of...
Jun 07, 2021 02:51 pm ET
EBS 11-DAY DEADLINE ALERT: Hagens Berman Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, June 18th Deadline Approaching in Securities Fraud Lawsuit
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 04, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, PTON, RMO, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Romeo Power, Inc. (RMO) f/k/a RMG Acquisition Corp. (RMG)Class Period: 10/5/2020 - 3/30/2021Lead...
Jun 04, 2021 12:30 pm ET
DEADLINE ALERT for RMO, CS, FUV, EBS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 03, 2021 06:07 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc. of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf of investors who purchased or acquired Emergent common stock...
Jun 03, 2021 03:56 pm ET
Entwistle & Cappucci LLP Announces It Has Filed a Securities Class Action Against Emergent BioSolutions Inc. (NYSE: EBS)
Entwistle & Cappucci LLP (“Entwistle & Cappucci” or “E&C”) today announced that the firm has filed a securities class action lawsuit on behalf of investors that purchased Emergent BioSolutions Inc.(“Emergent” or the “Company”) (NYSE: EBS) common stock from April 24, 2020 through April 16, 2021, inclusive. A copy of the complaint is available at:
Jun 03, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent”...
Jun 03, 2021 10:00 am ET
EBS, CCIV & PTON Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 02, 2021 11:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jun 02, 2021 09:58 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
Jun 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Arcimoto, Inc. (NASDAQ: FUV), Churchill Capital Corporation IV (NYSE: CCIV),...
Jun 02, 2021 04:11 pm ET
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EBS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the “Class Period”), of the important June 18, 2021...
Jun 02, 2021 11:00 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 01, 2021 10:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, EBS and RMO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canaan Inc. (CAN)Class Period: February 10, 2021 and April 9, 2021Lead Plaintiff Motion Deadline: June 14,...
Jun 01, 2021 05:38 pm ET
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, Securities Fraud Class Action Filed, Deadline Approaching
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 31, 2021 10:15 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, PTON, RMO, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Romeo Power, Inc. (RMO) f/k/a RMG Acquisition Corp. (RMG)Class Period: 10/5/2020 - 3/30/2021Lead...
May 30, 2021 01:00 pm ET
EBS DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP – Important June 18, 2021 Deadline Reminder for Emergent BioSolutions Inc. Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that the firm has filed a securities fraud class action lawsuit in the United States District Court for the District of...
May 28, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 27, 2021 10:23 pm ET
Emergent BioSolutions, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Emergent BioSolutions, Inc. (NYSE: EBS) investors that acquired shares between April 24, 2020, and April 16, 2021. Investors have until June 18, 2021 to...
May 27, 2021 07:45 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action –
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the “Class Period”), of the important June 18, 2021...
May 26, 2021 10:43 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, GOEV, PTON, RMO, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 - 3/29/2021Lead Plaintiff Motion Deadline: June 1,...
May 26, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Arcimoto, Inc. (NASDAQ: FUV), Churchill Capital Corporation IV (NYSE: CCIV),...
May 26, 2021 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
May 26, 2021 04:08 pm ET
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired Emergent common stock...
May 26, 2021 12:00 pm ET
DEADLINE ALERT for RMO, CS, FUV, EBS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 26, 2021 11:45 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 26, 2021 06:30 am ET
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate...
May 25, 2021 10:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, EBS and RMO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canaan Inc. (CAN)Class Period: February 10, 2021 and April 9, 2021Lead Plaintiff Motion Deadline: June 14,...
May 25, 2021 10:00 am ET
EBS, CCIV & PTON Shareholder Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 25, 2021 08:00 am ET
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn...
May 24, 2021 11:10 pm ET
CAN, CS, EBS, RMO SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 23, 2021 11:05 am ET
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, Securities Fraud Class Action Filed
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 22, 2021 05:08 pm ET
Investor Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired...
May 21, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, GOEV, PTON, RMO, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 - 3/29/2021Lead Plaintiff Motion Deadline: June 1,...
May 21, 2021 07:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action – EBS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the “Class Period”), of the important June 18, 2021...
May 21, 2021 11:15 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 21, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent”...
May 20, 2021 09:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
May 20, 2021 09:55 am ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.’s Directors and Officers for Breach of Fiduciary Duties – EBS
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Emergent BioSolutions Inc. (“Emergent BioSolutions”) (NYSE: EBS) for breaching...
May 19, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Arcimoto, Inc. (NASDAQ: FUV), Churchill Capital Corporation IV (NYSE: CCIV),...
May 19, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 19, 2021 12:00 pm ET
DEADLINE ALERT for RMO, CS, FUV, EBS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 18, 2021 10:56 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, EBS and RMO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canaan Inc. (CAN)Class Period: February 10, 2021 and April 9, 2021Lead Plaintiff Motion Deadline: June 14,...
May 18, 2021 07:08 pm ET
Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that the firm has filed a securities fraud class action lawsuit in the United States District Court for the District of...
May 18, 2021 03:24 pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. (“Emergent BioSolutions” or “the Company”) (NYSE:
May 18, 2021 11:56 am ET
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, Securities Fraud Class Action Filed
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs...
May 17, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, GOEV, RMO, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Vroom, Inc. (VRM)Class Period: 6/9/2020 - 3/3/2021Lead Plaintiff Motion Deadline: May 21, 2021SECURITIES...
May 14, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 14, 2021 07:40 pm ET
Kessler Topaz Meltzer & Check, LLP Files a Shareholder Class Action Lawsuit Against Emergent BioSolutions Inc. (NYSE: EBS) for Violations of Federal Securities Laws With Expanded Class Period
The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the “Class Period”). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-CCB (the “Roth Action”), was filed in the United States District Court for the District of Maryland (Southern Division). To view a copy of the Roth Action compla
May 14, 2021 07:15 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EBS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”), of the important June 18, 2021 lead...
May 14, 2021 12:05 pm ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Arcimoto, Inc. (NASDAQ: FUV), Churchill Capital Corporation IV (NYSE: CCIV),...
May 13, 2021 01:41 pm ET
EBS INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 13, 2021 09:38 am ET
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn...
May 12, 2021 09:44 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 - 3/29/2021Lead Plaintiff Motion Deadline: June 1,...
May 12, 2021 01:01 pm ET
SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of Emergent BioSolutions Inc. (EBS) and Encourages Investors With More Than $300,000 in Losses to Contact the Firm
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”)...
May 11, 2021 10:32 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, EBS and RMO
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canaan Inc. (CAN)Class Period: February 10, 2021 and April 9, 2021Lead Plaintiff Motion Deadline: June 14,...
May 10, 2021 11:24 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 10, 2021 05:15 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”), of the important June 18, 2021 lead plaintiff deadline.
May 10, 2021 01:27 pm ET
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on...
May 08, 2021 11:41 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed
Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.   Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs...
May 07, 2021 10:44 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 - 3/29/2021Lead Plaintiff Motion Deadline: June 1,...
May 07, 2021 11:00 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 06, 2021 02:35 pm ET
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland...
May 06, 2021 06:30 am ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL...
May 05, 2021 10:58 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CAN, CS, EBS, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canaan Inc. (CAN)Class Period: 2/10/2021 -...
May 05, 2021 10:08 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Arcimoto, Inc. (NASDAQ: FUV), Emergent BioSolutions, Inc. (NYSE: EBS), and Verus...
May 05, 2021 07:45 pm ET
EBS INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – EBS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”), of the important June 18, 2021 lead...
May 05, 2021 04:05 pm ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings...
May 05, 2021 04:00 pm ET
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.